113642-05-0

Usage

Uses

Used in Organic Synthesis:
Methyl 3-Bromo-4-Ethylbenzoate is used as a building block in organic synthesis for its ability to form more complex molecules, which are essential in the development of new pharmaceuticals and materials.
Used in Pharmaceutical Research:
In pharmaceutical research, Methyl 3-Bromo-4-Ethylbenzoate is utilized as a key intermediate, contributing to the creation of innovative drugs and therapeutic agents.
Used in Agrochemical Production:
Methyl 3-Bromo-4-Ethylbenzoate is employed as an intermediate in the production of agrochemicals, playing a crucial role in the development of new pesticides and other agricultural chemicals.
Used in Specialty Chemicals Industry:
Methyl 3-Bromo-4-Ethylbenzoate is also used in the production of specialty chemicals, where its unique properties and reactivity are harnessed to create specific chemical products for various applications.

InChI:InChI=1/C10H11BrO2/c1-3-7-4-5-8(6-9(7)11)10(12)13-2/h4-6H,3H2,1-2H3

Upstream product

• 67-56-1 methanol 
• 99548-53-5 3-Bromo-4-ethylbenzoic acid 
• 77-76-9 2,2-dimethoxy-propane 
• 619-64-7 p-ethylbenzoic acid 

Downstream Products

• 1421589-72-1 C₂₉H₃₅N₅O₃ 
• 1421589-42-5 C₂₄H₂₇N₅O 
• 684249-28-3 3-cyano-4-ethyl-benzoic acid 
• 1421589-69-6 C₁₅H₂₃NO₃ 
• 1421589-70-9 C₁₅H₂₁NO₃ 
• 684249-27-2 methyl 3-cyano-4-ethyl-benzoate 
• 113655-82-6 benzyl 2-chlorobenzocarbacephem-4'-carboxylate 
• 907584-59-2 benzyl 2-hydroxybenzocarbacephem.-4'-carboxylate 
• 113642-11-8 methyl m-bromo-p-<1-hydroxy-2-(4-oxoazetidin-2-yl)ethyl>benzoate 
• 86951-27-1 methyl m-bromo-p-<(4-oxoazetidin-2-yl)acetyl>benzoate 
• 113641-97-7 3-Bromo-4-(1-trimethylsilanyloxy-vinyl)-benzoic acid methyl ester 
• 113642-06-1 methyl p-acetyl-m-bromobenzoate 

Relevant academic research and scientific papers

Discovery and optimization of potent broad-spectrum arenavirus inhibitors derived from benzimidazole and related heterocycles

A series of potent arenavirus inhibitors sharing a benzimidazole core were previously reported by our group. SAR studies were expanded beyond the previous analysis, which involved the attached phenyl rings and methylamino linker portion, to include modifications focused on the benzimidazole core. These changes included the introduction of various substituents to the bicyclic benzimidazole ring system along with alternate core heterocycles. Many of the analogs containing alternate nitrogen-based bicyclic ring systems were found to retain antiviral potency compared to the benzimidazole series from which we derived our lead compound, ST-193. In fact, 21h, built on an imidazopyridine core, possessed a near tenfold increase in potency against Lassa virus pseudotypes compared to ST-193. As found with the benzimidazole series, broad-spectrum arenavirus activity was also observed for a number of the analogs discovered during this study.

Atroposelective radical aryl migration reactions from sulfur to carbon

The paper describes stereoselective radical aryl migration reactions from sulfur in sulfonates to aryl radicals for the synthesis of axially chiral biaryls. A chirality center in secondary benzylic sulfonates is used to diastereoselectively (atroposelectively) install a stereogenic axis via a 1,5 aryl migration reaction. Atroposelectivity has not been investigated in stereoselective radical chemistry before. Good yields (53-82%) but low selectivities (up to 2 to 1) were obtained.

SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS

The present invention relates to novel piperazine and azepine derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurodegenerative disorders including Alzheimer's disease.

Synthesis of Benzocarbacephem and Benzocarbapenem Derivatives by Copper-promoted Intramolecular Aromatic Substitution

Copper-mediated cyclisation of 4-azetidinones and 4-azetidinones proved to be a route to benzocarbacephem and benzocarbapenem derivatives respectively.The effect of functionalities present in the alkyl part of the ring to be formed was considered with regard to cyclisation efficiency and further chemical modifications.Conversion, into halide, of the diastereoisomeric mixture (4R,6S; 4S,6R; 4R,6R; and 4S,6S) of t-butyl 2-hydroxybenzocarbacephem-4'-carboxylate (14f) afforded either the chloride (17a) as racemic diastereoisomers or the fluoride (17c) as a single racemic diastereoisomer.The corresponding free carboxylic acids (18a, c) were designed as inactivators of beta-lactamases.